Pfizer: Wide Moat and Interesting Ichimoku Clouds

After the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock.

The current price is above Ichimoku Green Cloud, and it coincides with the Lagging Span. I will expect a bullish progression of the price in the long term with the market correctly evaluating the new strategy. However, I see a risk of profit-taking in the next sessions anyhow, not so significant to let the stock test the upper support of the green cloud.

Please, note that this analysis applies to long term positions.

Don't forget to support this idea, if you liked it, and to follow me, here on TradingView.
If you have another trading plan, please share in comments!

Investing Fellow

Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.

交易進行

Further gains are possible. I'm still maintaining the trade open.